Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ipsen CEO To Feed Group's Three Therapeutic Engines Fresh Assets In 2018

Executive Summary

CEO David Meek Says Ipsen has more than $1bn for M&A use to expand its product line in oncology, neuroscience and rare diseases.

Advertisement

Related Content

Merrimack's Prospects Dim As MM-141 Fails Pancreatic Cancer Phase II Trial
Exelixis CEO Eyes Expanded Indications For Cabozantinib
Ipsen Pays $575m Upfront For Struggling Pancreatic Drug Onivyde

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100408

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel